Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
80
resultados
Última actualización
17/10/2025 [07:15:00]
Resultados 25 a 50 de 80
Resumen de: CN120550103A
一种基于细菌外膜囊泡的口服疫苗制备方法及其应用，可有效应用于制备预防或治疗肠道黏膜病原体感染的药物，克服传统注射型疫苗依从性差、黏膜免疫反应低的问题。首先制备粪产碱杆菌的细菌外膜囊泡，然后制备DSPE‑PEG‑antigen，将两者混合后搅拌，制得OMV‑DSPE‑PEG‑antigen，取菊粉溶于PBS中，加热振荡，冷却至室温，加入OMV‑DSPE‑PEG‑antigen，搅拌，放置，得成品口服疫苗。制备工艺简单，方法稳定可靠，易操作，生产成本低，制备的基于细菌外膜囊的口服疫苗可有效激发肠道黏膜免疫应答，预防黏膜病原体的感染，经济和社会效益显著。
Resumen de: WO2024155027A1
The present invention relates to an attenuated Salmonella gallinarum expressing FliC or FliC-hiL2 and use thereof. The Salmonella strain according to the present invention has excellent immune activity and exhibits excellent anti-cancer efficacy, and thus can be used as a therapeutic agent for cancer together with or independently of existing anti-cancer drugs.
Resumen de: WO2025175111A1
Two stage heated water treatment of shell eggs results in-shell poached eggs. The in-shell poached are sufficiently cooked so when the eggs are cracked onto a plate the eggs have the characteristics of conventional poached eggs without further cooking and need only to be warmed for consumption. The in-shell poached eggs are also pasteurized in the shell to meet the FDA and WHO requirement of a 5-log reduction of Salmonella Enteritidis.
Resumen de: WO2025171792A1
Provided is use of a combination of three or more of the following microorganisms in the preparation of an anti-tumor combination vaccine: Bordetella pertussis, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, Proteusbacillus vulgaris, Lactic acid bacteria, Bifidobacterium longum, Bordetella pertussis, Corynebacterium diphtheriae and Clostridium tetani, Clostridium acetobutylicum, Salmonella typhimurium, and Streptococcus pyogenes. The anti-tumor combination vaccine is broad-spectrum, safe and non-toxic, and thus has the prospect of clinical applications.
Resumen de: US2025261659A1
Two stage heated water treatment of shell eggs results in-shell poached eggs. The in-shell poached are sufficiently cooked so when the eggs are cracked onto a plate the eggs have the characteristics of conventional poached eggs without further cooking and need only to be warmed for consumption. The in-shell poached eggs are also pasteurized in the shell to meet the FDA and WHO requirement of a 5-log reduction of Salmonella Enteritidis.
Resumen de: KR20240015036A
The present invention relates to a recombinant expression vector for secretion of ifn-03b2# protein and an attenuated salmonella strain transformed by the same. provided are a recombinant expression vector comprising a flgm gene, an ifn-03b2# gene, and a flhdc gene, an attenuated salmonella strain transformed by the same, and a pharmaceutical composition for treating cancer comprising the attenuated salmonella strain as an active ingredient.
Resumen de: CN120051482A
The present invention relates to a modified live attenuated Gram-negative bacterium wherein the bacterium has been modified such that an RNA molecule can be safely and efficiently delivered to a target eukaryotic cell. Thus, the present invention relates to a bacterial delivery system and various uses and methods thereof.
Resumen de: KR20240015036A
The present invention relates to a recombinant expression vector for secretion of ifn-03b2# protein and an attenuated salmonella strain transformed by the same. provided are a recombinant expression vector comprising a flgm gene, an ifn-03b2# gene, and a flhdc gene, an attenuated salmonella strain transformed by the same, and a pharmaceutical composition for treating cancer comprising the attenuated salmonella strain as an active ingredient.
Resumen de: WO2025170108A1
The present invention relates to identifying and engineering a tail spike protein gene from a genome of bacteriophage SFP10 infected with a Salmonella strain, purifying and producing a recombinant protein using mSFP10TSP, which is a recombinant protein formulation for detecting Salmonella enterica, EGFP-mSFP10TSP fused with a green fluorescent protein, and SiBD-mSFP10TSP fused with an SiBD, and thereby specifically detecting the Salmonella strain.
Resumen de: CN120484082A
The invention relates to the technical field of biology, in particular to an antibacterial peptide Aquiluscidin-1, a coding gene and application of the antibacterial peptide Aquiluscidin-1. The invention provides an antibacterial peptide Aquiluscidin-1 which has good thermal stability, acid-base stability and endogenous protease degradation resistance, can obviously inhibit the growth of escherichia coli, salmonella and staphylococcus aureus, and has good application prospects in the fields of food, hygienic products, cosmetics, biopesticide, biological feed additives or natural food preservatives and the like. Wide application prospects are realized.
Resumen de: CN120484133A
本发明提供了一种基于猪圆环病毒2型(PCV2)纳米抗体与沙门氏菌鞭毛蛋白的重组融合蛋白及其制备方法与应用。本发明将PCV2衣壳蛋白(Cap)特异性纳米抗体基因与沙门氏菌鞭毛蛋白基因融合，使用大肠杆菌原核表达系统表达制备了Nbcap‑flagellin重组融合蛋白。该重组融合蛋白能够利用Cap蛋白特异性纳米抗体的靶向结合能力，实现鞭毛蛋白佐剂与抗原蛋白的动态偶联，形成佐剂用量可调控的抗原‑佐剂复合物；在充分发挥鞭毛蛋白作为免疫佐剂作用的同时，突破传统鞭毛蛋白与抗原蛋白融合表达导致的固定佐剂‑抗原配比限制，提升了疫苗设计的灵活性，避免了细菌鞭毛蛋白过量可能引发的炎性反应，为开发高效、安全且广谱的PCV2亚单位疫苗提供了新的技术路径。
Resumen de: CN120478388A
The invention discloses antibacterial application of mulberry polysaccharide, and the mulberry polysaccharide is prepared by the following method: drying fresh mulberry, crushing, and adding into absolute ethyl alcohol for extraction; then taking the precipitate and drying; adding into distilled water, performing water bath, centrifuging, taking supernate, performing vacuum concentration, centrifuging again, taking precipitate, adding distilled water into the precipitate, redissolving, and drying to obtain mulberry polysaccharide; the mulberry polysaccharide obtained by the method has a relatively good inhibition effect on gram-negative bacteria escherichia coli and salmonella and gram-positive bacteria staphylococcus aureus; the antibacterial effect is enhanced along with the rise of the temperature, so that the heat stability is achieved, and meanwhile, the good antibacterial effect is achieved in both acid and alkali environments; the mulberry polysaccharide can be further prepared into a novel natural bacteriostatic agent and has a wide application prospect in the fields of daily chemicals and medicines.
Resumen de: CN120485133A
The invention discloses a salmonella bacteriophage Y1 with a wide lysis spectrum and a preparation method of a low-endotoxin preparation of the salmonella bacteriophage Y1. The preservation number of the salmonella bacteriophage Y1 is CCTCC M 20242911. The method comprises the following steps: adding a chitosan solution into a bacteriophage suspension, uniformly mixing, and precipitating overnight at room temperature. The salmonella phage Y1 disclosed by the invention is high in cracking capacity and can be applied to preparation of drugs for preventing and treating salmonella. The method disclosed by the invention is low in cost, simple in used equipment, simple and convenient in operation procedure, stable in effect, easy for large-scale industrial production, low in endotoxin preparation 3, good in endotoxin removal effect and small in influence on the activity of the bacteriophage.
Resumen de: CN120484134A
The invention relates to the technical field of biology, in particular to hermetia illucens antibacterial peptide H3 fusion protein, a construction method and application. The novel hermetia illucens antibacterial peptide H3 fusion protein provided by the invention not only has the antibacterial activity of the antibacterial peptide, but also has the activity of glucoside hydrolase, can realize rapid visual monitoring of the activity of the antibacterial peptide, has an inhibition effect on escherichia coli, salmonella and staphylococcus aureus, and can be used for preparing the antibacterial peptide H3 fusion protein. In the fields of food, hygienic products, cosmetics, biopesticides, biological feed additives or natural food preservatives and the like, the method has a wide application prospect.
Resumen de: WO2025170108A1
The present invention relates to identifying and engineering a tail spike protein gene from a genome of bacteriophage SFP10 infected with a Salmonella strain, purifying and producing a recombinant protein using mSFP10TSP, which is a recombinant protein formulation for detecting Salmonella enterica, EGFP-mSFP10TSP fused with a green fluorescent protein, and SiBD-mSFP10TSP fused with an SiBD, and thereby specifically detecting the Salmonella strain.
Resumen de: WO2025170306A1
The present invention relates to an antibacterial composition comprising, as an active ingredient, a plantaricin peptide derived from a Lactiplantibacillus plantarum KM2 strain, wherein the plantaricin peptide derived from the strain and a plantaricin peptide combination were found to have antimicrobial activity against at least one selected from the group consisting of Flavobacterium sp, Enterococcus faecalis, Listeria monocytogenes, Staphylococcus aureus, and acromobacter xylosoxidans (Alcaligenese xylosoxidans), Salmonella enterica, <i />and Vibrio parahaemolyticus, and the plantaricin peptide and the plantaricin peptide combination were found to have antibacterial activity and a cell wall lysis effect against the Flavobacterium sp. strain, and accordingly, the plantaricin peptide derived from the Lactiplantibacillus plantarum KM2 strain and the plantaricin peptide combination are provided as antimicrobial agents.
Resumen de: KR20250122779A
구현예의 수의학적 조성물은 가금류의 대장균 또는 살모넬라균에 의한 설사 증상의 치료 또는 완화용도를 갖는 것으로, 색도 L이 77 이하인 액상이고, 유효성분 및 항산화제를 포함하고, 상기 유효성분은 아프라마이신 또는 이의 염을 유효성분을 포함한다. 구현예의 수의학적 조성물은 조류의 대장균증 또는 추백리의 치료 또는 완화용으로 그 효과가 우수하다. 또, 구현예의 수의학적 조성물은 아프라마이신 또는 이의 염을 유효성분으로 포함하는 액상 조성물로 유효성분에 대한 조성물의 보관 안정성이 우수하고, 투여가 용이한 장점도 있다.
Resumen de: CN120464525A
The invention discloses a bacillus cereus JBH-LY1 strain and an application of the bacillus cereus JBH-LY1 strain in aquaculture, and relates to the technical field of microorganisms. The bacillus cereus JBH-LY1 is preserved in the China General Microbiological Culture Collection Center on June 6, 2024, and the preservation number of the bacillus cereus JBH-LY1 is CCTCC (China Center for Type Culture Collection) NO: M 20241168. The bacillus cereus is natural, safe, acid-resistant, alkali-resistant and high-temperature-resistant, has strong capability of producing protease, amylase, lipase and cellulase, and has a bacteriostatic effect on escherichia coli, salmonella typhimurium, staphylococcus aureus and aeromonas hydrophila. The bacillus cereus is used in the aquaculture industry, can purify aquaculture water and reduce the content of nitrogen and phosphorus, and also can regulate intestinal flora balance of cultured animals, promote growth, improve disease resistance and increase culture benefits.
Resumen de: CN120468246A
The invention provides a magnetic control type electrochemical biosensor of MWCNTs-MoS2 based on CRISPR (clustered regularly interspaced short palindromic repeats)/Cas12a as well as a preparation method and application of the magnetic control type electrochemical biosensor. The magnetic control type electrochemical biosensor comprises an aminated multi-walled carbon nanotube-molybdenum disulfide modified screen-printed carbon electrode, wherein a CRISPR-crRNA-Target DNA ternary complex and a ferroferric oxide-gold-single-stranded nucleotide probe are dropwise added on the surface of the screen-printed carbon electrode, and the probe is sheared after the reaction of the CRISPR-crRNA-Target DNA ternary complex and the ferroferric oxide-gold-single-stranded nucleotide probe; the magnetic control type electrochemical biosensor respectively shows wide linear response in the range of 4.6 * 10 < 1 >-4.6 * 10 < 7 > CFU/mL of staphylococcus aureus and 5.5 * 10 < 7 > CFU/mL of salmonella, the detection limit of the magnetic control type electrochemical biosensor to two pathogenic bacteria is as low as 2CFU/mL, and the magnetic control type electrochemical biosensor has good specificity to interfering bacteria, can be used for rapid detection of food safety and has good practicability.
Resumen de: KR20250121172A
E. coli O157:H7을 감염하는 두 종의 박테리오파지 SFP10과 PhiV10로부터 얻은 tail spike protein(TSP)를 엔지니어링 하여 항체를 사용하지 않고도 식품 내 E. coli O157:H7균을 신속하게 검출할 수 있는 방법 및 이의 방법으로 제작된 재조합 단백질이다.
Resumen de: KR20250121896A
본 발명은 사람에서 세균성 식중독을 일으키는 주요 원인균인 S. Enteritidis 및 S. Typhimurium, 그리고 가금에서 폐사를 일으키는 가금티푸스 원인균인 S. Gallinarum에 대한 산란계에서의 효과적인 살모넬라균 감염 예방을 위한 최적의 예방 프로그램 확립을 위한 발병을 수행하였다. 약독화 생균 백신만을 접종한 경우와 3가 살모넬라 불활화 사균체 백신만을 단독 접종한 산란계 모두에서 폐사는 발생하지 않았지만, 내부 장기 및 맹장 그리고 총 배설강 등에서 도전감염 균주가 분리되었다. 하지만 시판 백신인 약독화 생균 백신인 SG9R을 1차로 피하 접종한 후, 3가 살모넬라 불활화 사균체 (살모넬라 엔터라이티디스, 살모넬라 타이피뮤리움, 살모넬라 갈리나룸 불활화 사균체) 백신으로 추가로 근육 접종할 경우에는 내부 장기 및 맹장과 총배설강 등지에서 도전감염 균주가 분리되지 않았다. 이를 통해 약독화 생균 백신 및 3가 살모넬라 불활화 사균체 백신을 단독으로 접종한 경우보다 약독화 생균 백신 접종 후, 3가 살모넬라 불활화 사균체 백신을 추가로 접종할 경우 산란계에서 주요 살모넬라균을 효과적으로 예방할 수 있음이 확인하였다.
Resumen de: CN120464522A
The invention discloses bacillus subtilis capable of strongly inhibiting clostridium perfringens and relates to the technical field of microorganisms, the bacillus subtilis is preserved in China General Microbiological Culture Collection Center on November 25, 2024, the preservation number is CGMCC No.32783, the bacillus subtilis is classified and named as bacillus subtilis, and the bacillus subtilis is preserved in the China General Microbiological Culture Collection Center on November 25, 2024. The bacillus subtilis is bacillus subtilis which can produce surfactin well and has a strong inhibition effect on clostridium perfringens, and the bacillus subtilis also has a certain inhibition effect on large intestines, salmonella and staphylococcus aureus.
Resumen de: CN120459191A
The invention provides a novel application of a cordate houttuynia extract as a salmonella type III secretion system (T3SS) inhibitor. Through construction of a mouse infection model and in-vitro experiments, the extract is proved to be capable of remarkably reducing the bacterial load of infected mouse liver and spleen tissues, relieving tissue pathological damage and reducing inflammatory cell infiltration. Mechanism research shows that the Houttuynia cordata extract can down-regulate the expression of T3SS key virulence protein SipA in a dose-dependent manner, interfere the function of a secretion system, and further block the secretion and expression of virulence factors. The potential application of the herba houttuyniae extract in the aspect of resisting salmonella toxicity is disclosed for the first time, and a development strategy and a technical basis of a T3SS inhibitor derived from a natural product are provided.
Resumen de: CN120459124A
The invention discloses a novel application of rutin in preparation of a salmonella type III secretion system (T3SS) inhibitor. By constructing a salmonella mouse infection model, the rutin is proved to be capable of remarkably improving the survival rate of infected mice, reducing the bacterial load of liver and spleen target organs and effectively relieving the tissue damage of intestinal tracts, livers and spleens. In-vitro tests show that rutin does not affect the growth of bacteria, and the mechanism of the rutin playing a protection role is that the expression of a salmonella T3SS virulence factor is specifically inhibited, so that the pathogenicity of salmonella is weakened. The invention discloses a potential application of rutin as a salmonella T3SS inhibitor, and provides a theoretical basis for development of related anti-infective drugs.
Nº publicación: CN120464710A 12/08/2025
Solicitante:
ZHUHAI ENCODE MEDICAL ENG CO LTD
\u73E0\u6D77\u5E02\u94F6\u79D1\u533B\u5B66\u5DE5\u7A0B\u80A1\u4EFD\u6709\u9650\u516C\u53F8
Resumen de: CN120464710A
The invention discloses a screening culture medium and a preparation method and application thereof, the screening culture medium comprises a basic culture medium and additives, and the additives comprise amphotericin B, vancomycin, ox bile salt, sodium deoxycholate and No.3 bile salt. According to the screening culture medium provided by the invention, a special infectious microbe inhibitor is added on the basis of a trisaccharide iron culture medium, so that most gram-negative enterobacter, staphylococcus aureus and part of fungi except salmonella enteritis subspecies and shigella cannot grow; the interference of the infectious microbes on the detection of the salmonella enteritis subspecies and the shigella is avoided, so that the fluorescent probe can be applied to the detection of the salmonella enteritis subspecies and the shigella in a clinical anus swab, and the sensitivity of color development is improved.
BOPI
Sede Electrónica
